Shikonin compound triggers prostate cancer cell death through heme oxygenase-1 and ERK/p38 pathways
Prostate cancer remains one of the most frequently diagnosed malignancies in men worldwide, and while localised disease can often be ...
Prostate cancer remains one of the most frequently diagnosed malignancies in men worldwide, and while localised disease can often be ...
A new study from researchers at the University of Michigan has identified a potential two-drug strategy for treating an aggressive ...
A new real-world study of nearly 5,000 men with metastatic hormone-sensitive prostate cancer suggests that one specific treatment milestone may ...
A targeted radioactive drug has moved closer to the front line of metastatic prostate cancer treatment, after a large international ...
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
In a significant advancement for prostate cancer treatment, the Phase III clinical trial NRG-GU005 has shed new light on the ...
In a groundbreaking study published in Annals of Biomedical Engineering, researchers have unveiled a promising novel approach in the treatment ...
For men undergoing radical prostatectomy to treat prostate cancer, the decision to follow surgery with radiation therapy can be a ...
In a landmark advancement in prostate cancer treatment, a pivotal phase III clinical trial has demonstrated that a condensed course ...
Investigators at the renowned UCLA Health Jonsson Comprehensive Cancer Center have made a significant breakthrough in the realm of prostate ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine